Related Experiment Video
Updated: Aug 11, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Chemotherapy for colorectal cancer
Sandeep Goyle1, Anthony Maraveyas
1Department of Academic Oncology, Princess Royal Hospital, Hull, UK.
Digestive Surgery
|February 16, 2006
Summary
Adjuvant chemotherapy improves survival for colorectal cancer patients. Novel agents and biological treatments offer promising advancements in managing both early-stage and metastatic disease.
Area of Science:
- Oncology
- Medical Oncology
Background:
- Colorectal cancer is a leading cancer diagnosis in the EU.
- Adjuvant chemotherapy with 5-fluorouracil/folinic acid (5FU/FA) is standard for node-positive colon cancer.
- Optimal regimens and treatment for node-negative patients remain under investigation.
Purpose of the Study:
- To review current practices and emerging treatments for colorectal cancer.
- To evaluate the role of adjuvant chemotherapy in Dukes B colon cancer.
- To discuss advancements in metastatic colorectal cancer therapy.
Main Methods:
- Review of randomized studies and clinical trial results.
- Analysis of established chemotherapy regimens (5FU/FA).
- Evaluation of novel agents (oxaliplatin, irinotecan) and biological treatments (bevacizumab, cetuximab).
Main Results:
- Adjuvant therapy is recommended for Dukes B colon cancer with adverse indicators.
- Newer agents like irinotecan and oxaliplatin show improved response rates and survival.
- Combinations with biological treatments yield promising results for survival and quality of life.
Conclusions:
- Chemotherapy significantly benefits colorectal cancer patients in both adjuvant and metastatic settings.
- Ongoing research focuses on optimizing treatment regimens and incorporating novel agents.
- Future directions include combination therapies with biological agents for enhanced outcomes.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...